| Nicole Tomkowich, DO | |
|
175 Madison Ave, Mount Holly, NJ 08060-2099 | |
| (609) 914-6000 | |
| Not Available |
| Full Name | Nicole Tomkowich |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Location | 175 Madison Ave, Mount Holly, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003476813 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 25MB11809000 (New Jersey) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | OT019399 (Pennsylvania) | Secondary |
| Entity Name | Virtua Medical Group, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649226515 PECOS PAC ID: 9830222397 Enrollment ID: O20100804000338 |
News Archive
Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors. But about one in every six breast tumors has none of these receptors. Such cancers, called triple-negative, are particularly aggressive and notoriously difficult to treat.
Receiving prompt treatment for common health problems like diabetes, pneumonia and high blood pressure can save patients trips to the hospital and thousands of dollars in medical care costs.
One of WHO's 3 strategic goals is to ensure that an additional 1 billion people in the world are protected by universal health coverage (UHC) by 2023 – able to access the services they need to keep healthy, without falling into poverty as a result.
Sober Living in Delray, Recovery Residences, in conjunction with the "Moment of Change - Intervention Approaches for Professionals - 32nd National Conference" is sponsoring the presentation of "Mood Disorders and Addictive Disorders: Current Treatment Strategies" at 7:00 PM on Wednesday, September 29th, 2010 at the Old Calypso Restaurant in Delray Beach, Florida.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicole Tomkowich, DO 301 Lippincott Dr Ste 410, Marlton, NJ 08053-4197 Ph: (856) 355-0340 | Nicole Tomkowich, DO 175 Madison Ave, Mount Holly, NJ 08060-2099 Ph: (609) 914-6000 |
News Archive
Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors. But about one in every six breast tumors has none of these receptors. Such cancers, called triple-negative, are particularly aggressive and notoriously difficult to treat.
Receiving prompt treatment for common health problems like diabetes, pneumonia and high blood pressure can save patients trips to the hospital and thousands of dollars in medical care costs.
One of WHO's 3 strategic goals is to ensure that an additional 1 billion people in the world are protected by universal health coverage (UHC) by 2023 – able to access the services they need to keep healthy, without falling into poverty as a result.
Sober Living in Delray, Recovery Residences, in conjunction with the "Moment of Change - Intervention Approaches for Professionals - 32nd National Conference" is sponsoring the presentation of "Mood Disorders and Addictive Disorders: Current Treatment Strategies" at 7:00 PM on Wednesday, September 29th, 2010 at the Old Calypso Restaurant in Delray Beach, Florida.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO).
› Verified 7 days ago
Dr. Sergey Moldavskiy, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 175 Madison Ave Fl 1, Mount Holly, NJ 08060 Phone: 609-914-6000 | |
Sarah F Campbell, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 175 Madison Ave Fl 1, Mount Holly, NJ 08060 Phone: 609-914-6000 | |
Rupal Kalariya, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 120 Madison Ave, Suite E, Mount Holly, NJ 08060 Phone: 609-267-0700 | |
Dr. Robin T Thornton, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 120 Madison Ave, Mount Holly, NJ 08060 Phone: 609-261-1160 | |
Dr. John Lochiel Panico, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 175 Madison Ave, Mount Holly, NJ 08060 Phone: 609-267-0700 Fax: 609-261-4801 | |
Shruthi Balakrishna, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 175 Madison Ave Fl 1, Mount Holly, NJ 08060 Phone: 609-914-6000 |